

- Ferrannini, E.; Buzzigoli, G.; Bonadonna, R.; Giorico, MA.; Oleggini, M.; Graziadei, L.; Pedrinelli, R.; Brandi, L. and Bevilacqua, S. (1997):** Insulin resistance in essential hypertension . *N Engl J Med* 317:350-357.
- Ferrari, P. (1998):** Efficacy of $\alpha 1$ adrenoceptive blocker on plasma cholesterol in hypertensive pat. *J. Clin. Pharm. Therapy* 16: 263 – 273 .
- Fossatip, S. (1982):** Principle Clin. Chem. 28:2077-80 *quoted from Boehringer Mannheim GMBH Diagnostic Manual.*
- Frishman, WH.; Eisen, G. and Lapsker, J. (1988):** Terazosin a new long-acting alpha adrenergic antagonist for hypertension. *Med clin North Am*;72:441-8.
- Furberg, CD. Psaty, BM. and Meyer, JV. (1995):** Nifedipine dose-related increase in mortality in patients with coronary heart disease. *Circulation*; 92:1326-1331.
- Furchgott, R.F. and Bhadrakom, S. (1953):** J. Pharmacol Exp. Therapeutic applications, 108: 129.
- Furchgott, R.F. and Zawadzki, J.V. (1980):** Nature (London) 288:373-376. Quoted from **Martens, J.R.; P.Y. and Gelband, C.H.(1998):** Prevention of renovasculr and cardiac pathophysiological changes in hypertension by angiotensin II type I receptor antisense gene therapy. *Proc. Natrl. Acad. Sci. USA* 95:2664-2669.

- Gerstein, HC. And Yusuf, S. (1996):** Dysglycaemia and risk of cardiovascular disease. *Lancet*; 347:949-950.
- Gifford, RW. Jr. (1989):** Resistant hypertension: introduction and definitions. *Hypertension* ;(suppl) 1165-1166.
- Gillenwater, JY.; Conn, RL. and Chrysant, SG. (1995):** Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension. *J. Urol*; 154:110-115.
- Gopaul, NK.; Anggard, EE.; Mallet, AL.; Betteridge, DJ.; Wolff, SP. and Nourooz-, Zadeh, J. (1995) :**Plasma 8-epi-PGF₂ a levels are elevated in individuals with non-insulin dependent diabetes mellitus. *FEBS lett*; 368:225-9.
- Gormley ; Lepor, H. and Wein,(1996) :** Evaluation of treatment response to drugs in benign prostatic hyperplasia .*Urol.Clin N.Amer.*,17:631.
- Graham, RM.; Thornell, IR.; Gain, JM.; Bagnoli, C.; Oates, H.F. and Stokes, GS. (1976):** Prazosin : The first dose phenomenon. *Br Med J*;21:1293-4.
- Grover and Scadding, G. (1986):** Mechanism of action of parasympathomimetic as regard CVS.*BMJ*,183:1008-1012
- Haffner ,SM. ; Ronnema, T .and Lakkso ,M.(2000):**Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*; 339:229-234.

- Hallfrisch, J.; Reiser, S. and Prather, ES. (1983):** Blood lipid distribution of hyperinsulinemic men consuming three levels of fructose. *Am. J. Clin. Nutr.*;37:740-8.
- Hambery, (2001):** Complications of hypertension. *Arch Intern Med.*;170:157-183.
- Harano, Y.; Kageyama, A.; Hirose, J.; Askura, Y.; Yokota, T.; Ikebuchi, M.; Suzuki, M. and Omae, Y. (1995):** Improvement of insulin sensitivity for glucose metabolism with long acting calcium channel blocker, amlodipine in essential hypertensive subjects. *Metabolism*; 44:315-9.
- Haywood, J.R.; Shaffer, R.A. and Fastenow, C. (1981):**Regional blood flow measurements with pulsed Doppler flowmeter in conscious rats.*Am.J.Physiol.*241:H273-H278.
- Hill, BA. (1971):** Principles of medical statistics 9th ed London: limited publication, 147-283.
- Hjerman, I. (1992):** The metabolic cardiovascular syndrome, syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome,. *J. Cardiovas. Pharmacol.*; 20:55.
- Howard, BV. and Howard, WJ. (1994) :** Dyslipidemia in non-insulin dependent diabetes mellitus. *Endocr Rev.* 15:263-74
- Hunt, J.; Kirby, R.S., and Scott, M.A.(1990):**Endothelial dysfunction and lipid metabolism.*Hypertension.(suppl II):*1165-1168.

- Hwang, IS. Ho. H; Hoffman, BB. and Reaven, GM. (1987) :**
Fructose induced insulin resistance & hypertension in rats.
Hypertension Dallas; 10:512-6.
- James, R. (1999):** Metabolic changes associated with hypertension
and antihypertension therapy. *Am. Heart. J., 122 : 932 – 5 .*
- Jansen, H.; Lammers, R.; Baggen, MGA. and Birkenhager, JC.**
(1989): Effects of doxazosin on lipids, lipoprotein lipase, and
cholesterol synthesis in the golden hamster. *J Cardiovasc*
Pharmacol 13 (suppl 2) :S5-S10.
- Jimenez, J.; Zungia-Guejardo, S.; Zinman, B. and Angel, A.**
(1987): Effects of weight loss in massive obesity on insulin
& C-peptide dynamics & sequential changes in insulin
production, clearance & sensitivity. *J.Clin.Endocrinal*
Metab.;64:661-8.
- Joint National Committee on Detection, Evaluation, and**
Treatment of High Blood Pressure (1999): The fifth report
of the Joint National Committee on Detection, Evaluation ,
and Treatment of High Blood Pressure (JNC V). *Arch Intern*
Med.,;153:154-183.
- Kane, (1990):** Terazosin a new trend in hypertension. *Am J*
Cardiol:81 362-80.
- Kaplan, NM. (1994):** Treatment of hypertension: drug therapy.
In:Kaplan NM. Clinical Hypertension. 6th ed. Baltimore Md:
Williams & Wilkins;:191-280.

- Khalil, R.A.; Lodge, N.J. and Van Breeman, C. (1990):** In Hypertension: Pathophysiology, Diagnosis, and Management. Laragh, J.H. & Brenner, B.M. (Raven, New York), pp.547-567.
- Klein, R. (1995):** Hyperglycemia and microvascular and macrovascular disease in diabetes. *Diabetes Care*;18:258-268
- Koh, ET.; Mueller, J.; Osilesi, O.; Knehans, A. and Resier, S. (1985):** Effects of fructose feeding on lipid parameters in obese & lean, diabetic & nondiabetic Zucker rats. *J.Nutr.*;115:1274-84.
- Kreiger, DR. and Landsberg, L. (1988):** Mechanisms in obesity related hypertension: role of insulin & catecholamines. *Am. J.Hypertension*;1:84-90.
- Kynel, JJ. (1986):** Pharmacology of terazosin. *Am J Med* 80 (Suppl SB):12.1986.
- Kynel, JJ.; Bush, EN. and Bucker, SA. (1982):** Alpha-adrenergic blocking properties of terazosin (Abstract). *Fed Proc*;41:1648.
- Kynel, JJ.; Hollinger, RE. and Oheim, KW. (1980):** (Abbott-45975): 2-[4{(tetrahydro-2- furanyl)} carbonyl-1-piperazinyl-6-7-dimethoxy-4- quinazolinamine HCL, a new antihypertensive agent of the quinazoline type. *Pharmacologist* 1980:22:272.

- Law, MR.; Wald, NU. and Thompson, SG. (1994):** By how much and how quickly dose reduction in serum cholesterol concentration lower risk of ischaemic heart disease *BMJ*;308:367-373.
- Leier, CV.; Patterson, SE. and Huss, P. (1986):** The hemodynamic and clinical responses to terazosin. A new alpha blocking agent. In congestive heart failure. *Am J Med Sci* 292:128.
- Lester, P. (1999):** Diabetes and Antioxidants *BMJ*;369:167-200
- Levy, D.; Gamison, R.; Savage, D.; Kannel, W. and Castelli, W. (1990):** Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med*;322:1561-1566.
- Lewis, JG. (1983):** Adverse reactions to calcium antagonists. *Drugs*; 25:196-222.
- Lewis, EJ.; Hunsicker, LG.; Bain, RP. and Rohde, RD. (1993):** for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. *N Engl J Med*; 329:1456-1462.
- Lithell, HO. (1991):** Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. *Diabetes Care*; 14:203-9.
- Lund Johansen, P. (1975):** Hemodynamic changes at rest and during exercise in long term prazosin therapy for essential hypertension *Postgrad Med J*.58 (suppl1):45-52.

- Lund Johansen, P.; Omvik, P. and Haugland, H.(1986):** Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise *Br J Pharmacol*;21:45S-54S.
- Luther, RR.; Glassman, HN. and Estep, CB. (1988):** Terazosin a new selective alpha adrenergic blocking agent : Results of long term treatment in patients with essential hypertension. *Am J Hypertens* 1:237S.
- Luther, RR.; Glassman, HN. and Sperzel, WD. (1986):** Terazosin : A new alpha 1-blocker for the treatment of hypertensionL A review of randomized. Controiled clinical trials of once-daily administration as monotherapy. *J Hypertens (Suppl)* :494.
- Macgregor, Shaw, J. and Valente. (1995):** Non pharmacological treatment of hypertension *Am.J.Hypertension* ; 10 (25:60-80).
- MacMahon, S.; Collins, G.; Rautaharju, P.; Cutler, J.; Neaton, J. and Prineas, R (1989):** For the Multiple Risk Factor Intervention Trial Research Group. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. *Am J Cardiol*; 63:202-210.
- Miles, PDG.; Levistti, M.; Reichart, D.; Khoursheed, M.; Mossa, AR. and Olfesky, IM. (1995):** Kinetics of insulin action in vivo: identification of rate limiting steps, *Diabetes.*;44:947-53.

Mizogami, S. and Hanazuka, M. (1982): Antihypertensive effect of 2-4 tetrahydro-2-furanyl carbonyl-1-piperazinyl-6,7-dimethoxy-4-quinazolinamine hydrochloride dihydrate [terazosin] *Jpn J Pharmacol*;32(suppl):174P.

Morales, (1993): ACE inhibitors as choice in diabetic Diabetes, Vol. 40 Supl. 2, September, 20-32

Mulvihill Wilson, J.; Gaffney, FA.; Pettinger, WA.; Blomqvist, CG.; Anderson, S. and Graham, RM. (1983): Hemodynamic and neuroendocrine responses to acute and chronic alpha adrenergic blockade with prazosin and phenoxybenzamine. *Circulation*;67:383-93

Nelson, RG.; Bennett, PH.; Beck, GJ.; Tan, M.; Knowler, WC. and Mitch, WE. (1996): Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. *N Engl J Med*; 335: 1636-1642.

Ng J, Gormley, GJ.; Stoner, E.; Cook, T. and Woodbridge, NJ. (1998): Prognostic value of PSA density for the diagnosis of prostate cancer in finasteride treated patients. *J Urol*; 149:449A.

Paget, G.T and Barent, I.M (1964): In evaluation of drug activates pharmacometries Eds. Laurence D,R. and Bacharach, A.L., 1-135. Academic press London and New York.

Pagliassotti MJ, Shahrokhi KA and Moscrello M, (2001):
Involvement of liver and skeletal muscle in sucrose induced
insulin resistanc: Dose-response studies. *Am.J. Physiol* .
266:R1637-R1644.

Pallaret, (1999): Sensitivity to insulin during treatment with atenolol
BMJ, 298 : 1152 – 1157.

Pfeffer, MA.; Braunwald, E. and Moye, L.A. (1992): Effect of
captopril on mortality and morbidity in patients with left
ventricular dysfunction after myocardial infarction: results of
the Survival and Ventricular Enlargement Trial (SAVE). *N*
Engl J Med.;327:669-667.

Pierdomenico, SD.; Mezzetti, A, and Lapenna, D. (1995): White
coat hypertension in patients with newly diagnosed
hypertension: evaluation of prevalence by ambulatory
monitoring and impact on cost of health care. *Heart*
J.;16:692-697.

Pinkney, J.; Stehouwer, C.; Coppack, S. and Yudkin, J. (1994):
Endothelial dysfunction : cause of insulin reistance syndrome
Diabetes, Vol. 46 Supl. 2, September, 9-13.

Psaty BM, Heckbert SR and Koepsell TD, (1995): The risk of
myocardial infarction associated with antihypertensive drug
therapies. *JAMA*,274:620-625.

- Quinones, MA.; Gaasch, W. and Alexander, JK. 1976):** Influence of acute changes in preload. Afterload . contractile state and heart rate on ejection and isovolumic indices of myocardial contractility in man. *Circulation*;53:293-302.
- Randle, PJ.; Priestman, DA. and Mistry, SC. (1994) :** Glucose fatty acid interactions and the regulation of glucose disposal. *J.Cell Biochem*.55:1-11.
- Ravichandran, (1997):** :diabetes and myocardial infarction *JAMA* :258 111:115
- Reaven, (2000):** insulin resistance as a step for diabetes *Circulation*, 102:1254-57.
- Reeves, RA. (1995):** Does this patient have hypertension how to measure blood pressure. *JAMA*; 273:1211-1218.
- Reid, j.L; Ziven, J.A. and kapin, I.J. (1975):** Central and peripheral adrenergic mech. In the development of experimental hypertension in rats. *Clin. Res.* 37; 569-76.
- Richard Bucala, and Manhasset, N.Y.(2000):** Diabetes, Vol. 55 suppl., 19-23.
- Robert, M. (2001):** Cardiovascular kinin – generating capability in hypertension in fructose – fed rats. *J. Hypertension*, 16 : 1273 – 77.
- Roland, (2001):** Risk of high blood pressure. *BMJ*; 311: 1100-1112.
- Rosman, (1990):** ACE inhibitors. *J Hypertens*; 10:107-116.

- Rowe, JW.; Young, JB.; Minaker, KL.; Stevens, AL.; Pallotta, J. and Landsberg, L. (1987):** Effect of insulin & glucose infusions on sympathetic nervous system activity in normal man. *Diabetes*; 30:219-25.
- Ruilope, L.M.; Lahera, V. and Romero, J.C. (1994):** Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans. *Hypertension* 23:2-9.
- Samuelsson, O.; Wilhelmsen, L.; Etmfeldt, D.; Pennert, K.; Wedel, H. and Wikstrand, J. (1985):** Predictors of cardiovascular morbidity in treated hypertension: results from the Primary Preventive Trial in Coteborg, Sweden. *J Hypertens*; 3:167-176.
- Shaw, JE.; Hodge, Am. de.; Gurter, M.; Chitson, P. and Zimmet, PZ. (1999):** Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. *Diabetologia*; 42: 1050-1054.
- Shinozaki, K.; Suzuki, M.; Ikebuchi, M.; Takaki Hara, Y.; Tsushima, M. and Harano, Y. (1995) :** Insulin resistance associated with compensating hyperinsulinemia as an independent risk factor for vasospastic angina. *Circulation*, 92:1749-57.

- Shionoiri, H.; Sugimoto, K.; Minamisawa, K.; Ueda, S.; Ebina, T.; Matsukawa, T.; Gotoh, and Ishii, M. (1990):** Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. *J Cardiovasc Pharmacol* 15:933-938.
- Shionoiri, H. (1997):** Glucose tolerance during chronic captopril therapy in essential hypertension. *J. Cardiovascular pharmacol.* 9: 160 – 164.
- Shwartz, (1992):** antihypertensive drugs *Am.J. Hypertension*;6 (16: 77-90.
- Siedel, JH.; Schlumberger, S.; Klose, J. and Washlefeld, AW. (1991):** *J. Clin. Chem. Clin. Bioch.* 19:838, quoted from Boehringer Mannheim GMBH Diagnostic Manual.
- Simonson, DC. (1988):** Etiology and prevalence of hypertension in diabetic patients. *Diabetes Care* 11:821-827.
- Smith, D. (1991):** The atherogenic effects of hyperinsulinemia. *Primary Cardiology*;17(3):65-7.
- Sowers, JR. (1991):** Is hypertension an insulin resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. *Am Heart J*;122:932-5.
- Sowers, J.R. (1999) :** Clinical implication of hypertension in diabetic patient. *Am J Hypertension*, 1999 : 130 : 415-424.

Stamler, J.; Vaccaro, O.; Neaton, JD. and Wentworth, D. (1993):

Diabetes other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. *Diabetes Care* 1993; 16: 434-444

Standel, E.; Balletshofer, B.; Dahl, B.; Weichenhain, B.; Stiegler,

and Hormann, A. (1996): Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich general practitioner project. *Diabetologia*; 39: 1540-1545

Steiner, G. (1991): Altering triglyceride concentration changes

insulin-glucose relationships in hypertriglyceridemic patients. Double blind study with gemfibrozil with implications for atherosclerosis. *Diabetes Care*; 14:1077-81.

Storlein, LH.; Kraegen, EW.; Jekins, AB. and Chisholm, DJ.

(1998): Effects of sucrose vs starch diets on in vivo insulin action, thermogenesis & obesity in rats. *Am. J.Clin. Nutr.*; 47:420-7.

Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull

CA, et al., (2000): Epidemiological association of glycaemia with macrovascular and microvascular complications of type 2 diabetes *BMJ*; 321: 405-412.

Susini, C. and Lavau, M. (1987):In vitro & in vivo responsiveness

of muscle & adipose tissue to insulin in rats rendered obese by a high fat diet. *Diabetes* 27:114-20.

- Taylor, WM.; Storlein, LH. and Jenkins, AB. (1988):** Effect of fructose on phenylephrine – induced glucose output in perfused rat liver. *Horm Metab. Res.*;20:528-30.
- Tesfamariam, B. (1994):** Free radicals in diabetic endothelial cell dysfunction. *Free Radic. Biol. Med*; 16:383-91.
- Thornburn, AW.; Storlein, LH.; Jenkins, AB.; Khouri, S. and Kraegen, EW. (1989):** Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. *Am.J.Clin. Nutr.*;49:1155-63.
- Trinder, P. (1969):** Enzymatic determination of glucose (single reagent) *Ann. Clin. Biochem*; 6:24.
- UK Prospective diabetes study (UKPDS), (1996):**diabetes and hypertension as risk factor of stroke. *Circulation*; 100:67-86.
- Ullian, ME.; Islan, M.M.; Robinson, C.J.; Fitzgibbon, W.R.; Tobin, E.T. and pavul, R.V. (1997):** Resistance to mineralocorticoids in wistar furth rats. *Am. J. Physiol.* 272: H 1454-H 1460.
- Usitupa M. J.; Niskanen, L. K.; Siitonen, O.; Voutilainen, E. and Pyorala, K. (1990):** 5 year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. *Circulation*; 82:27-36.

Vanhoutte, P.M.; Rubanyi, G.M. and Houston, D.S. (1986): Modulation of vascular smooth muscle contraction by the endothelium. *Ann. Rev. Physiol.* 48:307-320.

Verdecchia, P.; Porcellati, C.; Shillaci, G.; Borgioni, C.; ciucci, A. and Battistelli, M. (1994): Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. *Hypertension* 1994;24:793-801.

Vrana, A. and Kazadova, L. (1983): 2-Deoxyglucose transport into the diaphragm muscle of rats with fructose induced hypertriglyceridemia. *Nutr. Rep.Int.*;28:597-601 .

Walgren, MC.; Young, JB.; Kaufman, LN. and Landsberg, L. (1987): The effects of various carbohydrates on sympathetic activity in the heart & interscapular brown adipose tissue in the rat. *Metabolism*; 36:585-94.

Wareham, NJ.; Wong, MY. and Day, NE. (2001): Glucose intolerance and physical inactivity: the relative importance of low habitual energy expenditure and cardiorespiratory fitness. *Am J Epidemiol*; 152: 132-139.

Wood, DA.; DE Backer, G.; Faergeman, O.; Graham, J.; Mancina, G. and Pyorala, K. (1999): Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. *Eur Heart J*; 19: 1434-1503.

- Yokota, C.; Ikebuchi, M.; Suzuki, M.; Norioka, M.; Ikeela, K. Shirozoki, K. and Harano, Y. (1995):** *Insulin resistance rather than hyperinsulinemia more closely associated with essential hypertension. Clin. Exp. Hypertension.; 17:523-36.*
- Zavaroni, I.; Chen, Y. DI. and Reaven, GM. (1992):** *Studies of the mechanism of fructose induced hypertriglyceridemia in the rat. Am.J.Clin. Nutr.;53:1087-98.*